氨酸/氨酸激酶抑制剂的阿普利提安因类的化学演变
Lin Du1, Brice A P Wilson1, William J Moore2
1Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702, United States.
Journal of medicinal chemistry
|June 6, 2025
概括
研究人员开发出强大的海洋衍生的激酶抑制剂,向J-PKAcα,这是纤维状肝细胞癌 (FLHCC) 的关键参与者. 这些新型的阿普利提安因类型通过抑制癌细胞生长,显示出FLHCC治疗方法的前景.
科学领域:
- 生物化学 生物化学
- 药用化学 医学化学
- 在瘤学瘤学.
背景情况:
- 纤维状肝细胞癌 (FLHCC) 是一种罕见的肝癌.
- 嵌合基酶J-PKAcα是FLHCC的潜在治疗点.
研究的目的:
- 为了提高aplithianine A的功效,一种来自海洋的激酶抑制剂,对J-PKAcα.
- 为潜在的FLHCC治疗开发新的J-PKAcα抑制剂.
主要方法:
- 基于结构的设计和选的aplithianine类似物.
- 在三个类别中合成了150多种aplithianine类似物.
- 用X射线晶体学来确定结合模式.
- 用于选择性评估的基因组分析.
- 在体外ADME/毒素分析 (可溶性,透性,新陈代谢,hERG结合).
主要成果:
- 合成的阿普利提安因类型在对抗J-PKAcα时实现了低纳米分子生物化学IC50值.
- 二等级的阿普利提安因显示了一种新的结合方式,涉及DFG残留物Asp239.9.
- 选择的类似物抑制了细胞中的J-PKAcα活性,并在纳米分子度下对NCI-60癌细胞系表现出抗增殖作用.
结论:
- 新的阿普利提安因类型是J-PKAcα的强有力的抑制剂.
- 这些化合物表现出有前途的抗癌活性和一种新的结合机制.
- 阿普利蒂安因类型代表FLHCC的潜在治疗策略.
相关概念视频
Transducer Mechanism: Enzyme-Linked Receptors
2.9K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.9K
Drugs that Destabilize Microtubules
2.0K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Physical Properties of Amines
3.5K
Amines with low molecular weight are usually gaseous at room temperature, while those with high molecular weight are liquid or solids in nature. Usually, low molecular weight amines have a rotten fish-like smell. Diamines typically have a pungent smell. For instance, cadaverine and putrescine, depicted in Figure 1, are two molecules responsible for decaying tissue.
3.5K
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Inhibition of Cdk Activity
4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K


